Próximamente
Drug Discovery & Pharmaceutical Biotechnology
Lleva una diana de la hipótesis al primer ensayo en humanos.
El curso completo
- módulos
- 90
- temas
- 900
- min por lección
- 15
45%
de la carga global de enfermedad podría abordarse con ciencia concebible hoy.
Lo que sabrás hacer.
Decide si una diana merece perseguirse
Etapa 1 · Target Discovery & Validation
Criba sin perseguir artefactos de ensayo
Etapa 2 · Models, Assays & Screening
Lee relaciones estructura-actividad
Etapa 3 · Molecular Design & Medicinal Chemistry
Elige anticuerpo, oligo o terapia celular
Etapa 4 · Biologics & Advanced Modalities
Descarta pronto un candidato débil
Etapa 5 · Developability, Safety & Candidate Selection
Lee con honestidad un ensayo fase II
Etapa 6 · Clinical Development & Regulation
Siete etapas.Una sola subida constante.
Diana, hit, líder, candidato — y luego el ensayo que te dice la verdad.
90módulos
en 7 etapas
900temas
≈ 10 por módulo
≈225horas
en lecciones de 15 minutos
≈2,5años
≈15meses
≈7meses
para terminar el curso completo
- 1
Target Discovery & Validation
¿Es real siquiera esta diana?
9 módulos · 90 temas · ≈ 23 h
- 2
Models, Assays & Screening
Ensayos, cribados y sus artefactos
18 módulos · 180 temas · ≈ 45 h
- 3
Molecular Design & Medicinal Chemistry
Qué convierte una molécula en fármaco
14 módulos · 140 temas · ≈ 35 h
- 4
Biologics & Advanced Modalities
Anticuerpos, ARN, células, conjugados
17 módulos · 170 temas · ≈ 43 h
- 5
Developability, Safety & Candidate Selection
Exposición, seguridad y el no rotundo
18 módulos · 180 temas · ≈ 45 h
- 6
Clinical Development & Regulation
Ensayos, reguladores, evidencia
11 módulos · 110 temas · ≈ 28 h
- 7
Portfolio, Partnerships & Capstone
Patentes, socios, tu propio programa
3 módulos · 30 temas · ≈ 8 h
Meses
0612180369024
MesesMeta · ≈ 2,5 años · ≈ 15 meses · ≈ 7 meses
Las horas y los meses son estimaciones: una lección de 15 minutos por tema, cada día.
Cada módulo.Cada tema.
Los títulos de módulos y temas se quedan en inglés, el idioma de trabajo del sector.
Etapa 1
Target Discovery & Validation
¿Es real siquiera esta diana?
9 módulos · 90 temas
1Scope of Drug Discovery and Pharmaceutical Biotechnology10 temas
- Discovery, Preclinical Development, and Clinical Development
- Small Molecules, Biologics, and Advanced Therapeutic Modalities
- Target-Based and Phenotype-Based Discovery
- Therapeutic Hypotheses and Evidence Progression
- Discovery Tools, Research Probes, and Drug Candidates
- Product Quality, Biological Activity, and Clinical Benefit
- Multidisciplinary Responsibilities Across Development Stages
- Interfaces with Pharmacology and Disease-Specific Therapeutics
- Interfaces with Genetic Engineering and Biomanufacturing
- Decision Gates from Initial Concept to an Approved Product
2Unmet Medical Need and Indication Selection10 temas
- Defining the Disease and Intended Patient Population
- Current Treatment Options and Their Limitations
- Disease Burden and Patient-Relevant Outcomes
- Natural History and Progression Patterns
- Heterogeneity Within a Diagnostic Category
- Treatment Setting and Place in Therapy
- Prevention, Disease Modification, and Symptom Control
- Feasibility of Demonstrating Clinical Benefit
- Patient and Clinician Input into Development Priorities
- Selecting an Indication with a Testable Development Rationale
3Target Product Profiles and Development Objectives10 temas
- Intended Use and Desired Therapeutic Benefit
- Minimum Acceptable and Preferred Product Characteristics
- Route of Administration and Dosing Burden
- Efficacy, Safety, and Tolerability Goals
- Onset, Duration, and Reversibility of Effect
- Patient Selection and Diagnostic Requirements
- Storage, Delivery Device, and Care-Setting Constraints
- Differentiation from Existing and Emerging Treatments
- Translating Product Goals into Candidate Selection Criteria
- Updating the Product Profile as Evidence Accumulates
4Disease Biology and Therapeutic Hypothesis Formation10 temas
- Causal Mechanisms and Associated Biological Changes
- Disease Initiation, Maintenance, and Progression
- Cell Types and Tissue Compartments Involved
- Protective Responses and Pathological Responses
- Intervention Timing and Disease Stage
- Pathway Redundancy and Compensatory Mechanisms
- Genetic and Environmental Contributions
- Mechanistic Models and Competing Explanations
- Falsifiable Predictions of Therapeutic Intervention
- Evidence Needed Before Committing to a Discovery Program
5Human Genetics in Target Discovery10 temas
- Disease-Associated Variants and Candidate Targets
- Loss-of-Function and Gain-of-Function Evidence
- Rare Variants and Common Variant Associations
- Causal Gene Assignment at Associated Loci
- Direction of Effect and Therapeutic Modulation
- Natural Human Variation as Evidence of Target Tolerance
- Population Diversity and Generalizability
- Genetic Association and Therapeutic Causality
- Mendelian Randomization Concepts and Limitations
- Integrating Genetic Findings with Experimental Validation
6Molecular Profiling for Therapeutic Discovery10 temas
- Disease-Associated Transcriptional Programs
- Protein Abundance and Functional State
- Metabolic Changes and Therapeutic Opportunities
- Single-Cell Profiles and Disease-Relevant Populations
- Spatial Context and Tissue Organization
- Longitudinal Changes During Disease Progression
- Perturbation Signatures and Mechanistic Comparisons
- Confounding by Cell Composition and Treatment History
- Convergent Evidence Across Profiling Modalities
- Turning Molecular Associations into Testable Drug Hypotheses
7Target Prioritization and Evidence Assessment10 temas
- Biological Relevance and Causal Support
- Direction and Degree of Desired Target Modulation
- Tissue Distribution and Accessible Disease Compartments
- Target Redundancy and Functional Compensation
- Human Evidence and Preclinical Evidence Weighting
- Anticipated Safety Liabilities
- Modality Compatibility and Delivery Feasibility
- Availability of Assays and Experimental Models
- Competitive Landscape and Differentiation Potential
- Transparent Scoring and Decision-Making Under Uncertainty
8Experimental Target Validation10 temas
- Genetic Perturbation and Pharmacological Perturbation
- Orthogonal Approaches to the Same Target Hypothesis
- Acute and Chronic Target Modulation
- Rescue Experiments and Causal Interpretation
- Target Dosage and Partial Modulation
- Cell-Type-Specific and Context-Dependent Effects
- On-Target Activity and Secondary Biological Responses
- Reproducibility Across Models and Laboratories
- Negative Findings and Target Hypothesis Revision
- Defining Target Validation Milestones and Stop Criteria
9Target Tractability and Modality Selection10 temas
- Druggability and Biological Validity as Separate Questions
- Binding Pockets, Surfaces, and Molecular Accessibility
- Intracellular and Extracellular Targets
- Catalytic, Scaffolding, and Regulatory Functions
- Inhibition, Activation, Replacement, and Depletion Strategies
- Small-Molecule and Biologic Access Constraints
- Transient and Durable Therapeutic Interventions
- Target Abundance, Turnover, and Required Exposure
- Delivery Barriers and Tissue Selectivity
- Selecting a Modality from the Intended Therapeutic Mechanism
Etapa 2
Models, Assays & Screening
Ensayos, cribados y sus artefactos
18 módulos · 180 temas
10Chemical Probes and Research Reagents10 temas
- Probe Quality and Fitness for Purpose
- Potency, Selectivity, and Cellular Activity
- Negative Controls and Inactive Analogues
- Orthogonal Probes with Distinct Chemical Structures
- Concentration-Dependent Interpretation
- Reagent Identity, Purity, and Stability
- Antibody and Protein Reagent Validation
- Tool Compounds and Development Candidates
- Availability of Reliable Target Engagement Evidence
- Avoiding Mechanistic Conclusions from Inadequate Reagents
11Disease Model Selection and Qualification10 temas
- Fit-for-Purpose Models and Research Questions
- Construct, Face, and Predictive Validity
- Model Relevance to the Intended Patient Population
- Cell Lines and Disease-Specific Limitations
- Genetic Background and Environmental Context
- Model Phenotypes and Clinical Endpoints
- Positive Controls and Known Therapeutic Responses
- Biological Variability and Reproducibility
- Model Qualification Before Candidate Ranking
- Limits of Extrapolating Model Success to Clinical Benefit
12Primary Cells and Stem-Cell-Derived Models10 temas
- Primary Human Cells and Donor Variability
- Patient-Derived Materials and Clinical Annotation
- Induced Pluripotent Stem Cell Models
- Differentiation State and Functional Maturity
- Isogenic Comparisons and Background Effects
- Cell Identity and Phenotype Stability
- Culture-Induced Changes and Disease Fidelity
- Scaling Human Cell Models for Discovery
- Consent, Provenance, and Access to Biospecimens
- Integrating Human Cell Evidence into Candidate Decisions
13Organoids, Tissue Models, and Microphysiological Systems10 temas
- Three-Dimensional Models and Tissue Architecture
- Organoids and Patient-Derived Disease Models
- Organ-on-Chip Platforms and Controlled Microenvironments
- Multicellular Interactions and Stromal Components
- Perfusion, Mechanical Cues, and Tissue Function
- Model Access for Drug Delivery and Measurement
- Compound Distribution Within Complex Models
- Readout Standardization and Between-Batch Variability
- Benchmarking Against Human and Clinical Data
- Appropriate Uses and Remaining Predictive Limitations
14In Vivo Models in Discovery10 temas
- Selecting Models for Efficacy and Mechanistic Questions
- Spontaneous, Induced, and Genetically Defined Disease Models
- Species Differences in Target and Pathway Biology
- Disease Stage and Intervention Timing
- Exposure Confirmation and Pharmacodynamic Readouts
- Randomization, Blinding, and Prespecified Analyses
- Biological Sex, Age, and Background Effects
- Welfare, Replacement, Reduction, and Refinement Principles
- Replication and Cross-Model Confirmation
- Translational Interpretation of Positive and Negative Findings
15Assay Cascades and Discovery Decision Architecture10 temas
- Primary Screens and Follow-Up Assays
- Orthogonal Confirmation and Counterscreens
- Biochemical, Cellular, and Organism-Level Evidence
- Throughput and Biological Relevance Tradeoffs
- Assay Sequencing to Reduce False Positives
- Early Developability and Safety Filters
- Data Integration Across Different Readouts
- Compound Progression Criteria
- Iterative Refinement of the Assay Cascade
- Linking Assay Results to the Therapeutic Hypothesis
16Biochemical Assay Development10 temas
- Enzyme Activity and Reaction-Based Readouts
- Substrate Selection and Assay Context
- Initial Rates and Endpoint Measurements
- Assay Dynamic Range and Signal Stability
- Coupled Assays and Reagent Dependencies
- Controls for Direct Readout Interference
- Reproducibility and Plate-Level Variation
- Concentration-Response Curve Interpretation
- Apparent Potency and Assay Condition Dependence
- Qualification of Biochemical Assays for Screening
17Binding and Biophysical Characterization10 temas
- Affinity, Kinetics, and Binding Stoichiometry
- Association and Dissociation Rates
- Surface-Based and Solution-Based Measurements
- Thermal Stability and Binding-Related Shifts
- Calorimetric and Spectroscopic Binding Concepts
- Competition and Cooperative Binding
- Immobilization Effects and Experimental Artifacts
- Binding to Intended and Unintended Molecular States
- Orthogonal Confirmation of Physical Interaction
- Distinguishing Binding from Functional Modulation
18Cell-Based Functional Assays10 temas
- Endogenous and Engineered Cellular Readouts
- Reporter Systems and Biological Relevance
- Proximal and Distal Pathway Measurements
- Cell Permeability and Intracellular Availability
- Target Expression and Assay Sensitivity
- Cell Viability and Nonspecific Activity
- Time-Dependent Responses and Adaptation
- Culture Conditions and Apparent Drug Effects
- Phenotype Rescue and Functional Relevance
- Connecting Cellular Activity to Target Engagement
19High-Content and Imaging-Based Screening10 temas
- Multiparametric Cellular Phenotypes
- Image Acquisition and Biological Resolution
- Cell Segmentation and Feature Extraction
- Morphological Signatures and Phenotypic Similarity
- Subcellular Localization and Spatial Responses
- Time-Lapse Imaging and Dynamic Phenotypes
- Batch Effects and Image Analysis Bias
- Interpretable Features and Learned Representations
- Hit Selection from Complex Phenotypic Data
- Biological Confirmation Beyond Imaging Signatures
20High-Throughput Screening10 temas
- Screening Libraries and Chemical Diversity
- Assay Miniaturization and Automation
- Plate Layouts and Control Placement
- Assay Quality Metrics and Z-Prime Factor
- Normalization and Batch Correction
- Hit Thresholds and False Discovery Risk
- Compound Handling and Sample Integrity
- Primary Screening and Confirmation Strategy
- Data Traceability from Library Member to Result
- Evaluating Screen Quality Before Advancing Hits
21Hit Confirmation and Artifact Elimination10 temas
- Compound Identity and Purity Verification
- Independent Resupply and Activity Reconfirmation
- Concentration-Response Reproducibility
- Aggregation and Nonspecific Inhibition
- Fluorescence, Luminescence, and Detection Interference
- Reactive Chemistry and Assay Component Modification
- Cytotoxicity and General Stress Responses
- Promiscuous Activity and Frequent-Hitter Patterns
- Orthogonal Mechanistic and Biophysical Evidence
- Selecting Credible Starting Points for Optimization
22Phenotypic Drug Discovery10 temas
- Disease-Relevant Phenotypes Without a Preselected Target
- Rescue, Suppression, and State-Transition Readouts
- Phenotypic Screens in Human-Derived Models
- Multiparametric Efficacy and Toxicity Profiles
- Known Mechanism Comparators
- Phenotype Robustness Across Biological Contexts
- Hit Prioritization Without Complete Mechanistic Knowledge
- Linking Phenotypic Activity to Exposure
- Mechanistic Uncertainty and Development Risk
- When Phenotypic Evidence Supports Further Investment
23Target Deconvolution and Mechanism of Action10 temas
- Direct Binding Partners and Downstream Responders
- Chemoproteomic Approaches to Target Identification
- Genetic Sensitivity and Resistance Evidence
- Affinity Capture and Competition Concepts
- Thermal and Stability-Based Engagement Methods
- Perturbation Signatures and Pathway Inference
- Distinguishing Primary and Secondary Mechanisms
- Polypharmacology and Multiple Relevant Targets
- Causal Confirmation of the Proposed Mechanism
- Communicating Residual Mechanistic Uncertainty
24Fragment-Based Discovery10 temas
- Fragment Libraries and Low-Complexity Starting Points
- Detecting Weak but Specific Interactions
- Ligand Efficiency and Related Metrics
- Orthogonal Fragment Hit Confirmation
- Structural Information for Fragment Progression
- Fragment Growing, Linking, and Merging
- Maintaining Binding Quality During Molecular Expansion
- Solubility and Assayability Constraints
- From Fragment Hits to Lead-Like Molecules
- Evaluating Fragment Campaign Progress and Failure Modes
25Encoded and Display-Based Discovery Libraries10 temas
- DNA-Encoded Small-Molecule Libraries
- Phage and Other Display Platforms
- Selection-Based and Functional Screening Approaches
- Library Diversity and Representation
- Target Presentation and Selection Bias
- Enrichment and Binding Specificity
- Sequence or Barcode Identification
- Resynthesis and Off-Platform Confirmation
- Affinity Improvement and Functional Validation
- Limits of Inferring Drug Potential from Selection Enrichment
26Natural Products and Biologically Derived Leads10 temas
- Natural Product Chemical Diversity
- Extract-Based and Purified Compound Screening
- Dereplication and Known Compound Identification
- Activity-Guided Fractionation Concepts
- Mixture Effects and Misleading Activity Attribution
- Structural Elucidation and Identity Confirmation
- Supply, Synthesis, and Reproducibility Constraints
- Semisynthetic Optimization and Analogue Development
- Mechanistic Validation of Natural Product Leads
- Converting Biological Origin into a Reproducible Drug Program
27Drug Repurposing and Translational Repositioning10 temas
- New Indications for Existing Compounds
- Mechanism-Based and Phenotype-Based Repositioning
- Prior Human Exposure and Safety Evidence
- Formulation and Dose Differences Across Indications
- Tissue Exposure at Clinically Feasible Doses
- Biomarker and Patient Selection Opportunities
- Evidence Gaps Despite Previous Approval
- Intellectual Property and Commercial Feasibility
- Clinical Proof-of-Concept Strategy
- Distinguishing Plausible Repurposing from Unsupported Therapeutic Claims
Etapa 3
Molecular Design & Medicinal Chemistry
Qué convierte una molécula en fármaco
14 módulos · 140 temas
28Structure-Based Drug Design10 temas
- Experimental Structures and Structural Confidence
- Binding Site Geometry and Molecular Recognition
- Protein Flexibility and Alternative Conformations
- Water Networks and Solvation Effects
- Ligand Pose Interpretation
- Structure-Guided Optimization of Interactions
- Selectivity from Structural Differences
- Structural Limitations in Membrane and Disordered Targets
- Combining Structural and Functional Data
- Avoiding Overinterpretation of a Single Static Structure
29Virtual Screening and Computational Prioritization10 temas
- Ligand-Based and Structure-Based Screening
- Chemical Representations and Molecular Similarity
- Docking Scores and Pose Uncertainty
- Pharmacophore Models and Interaction Requirements
- Binding Energy Estimation Concepts
- Library Preparation and Molecular State Assignment
- Prospective Enrichment and Experimental Validation
- Applicability Domains and Dataset Bias
- Diversity-Aware Compound Selection
- Using Computation to Prioritize Experiments Rather Than Confirm Activity
30Machine Learning and AI-Assisted Discovery10 temas
- Prediction Tasks Across the Discovery Pipeline
- Assay Data Quality and Label Reliability
- Molecular Property and Activity Prediction
- Generative Design and Constraint Handling
- Protein Structure Predictions in Discovery Workflows
- Data Leakage and Misleading Retrospective Performance
- Out-of-Distribution Generalization
- Uncertainty-Aware and Active Learning Approaches
- Prospective Experimental Evaluation
- Reproducibility, Traceability, and Human Review of Model Proposals
31Medicinal Chemistry and Structure-Activity Relationships10 temas
- Chemical Series and Matched Molecular Comparisons
- Potency Trends and Activity Cliffs
- Substituent Effects on Binding and Function
- Stereochemistry and Biological Activity
- Bioisosteric Replacement Concepts
- Conformational Restriction and Molecular Flexibility
- Synthetic Accessibility and Iteration Speed
- Multiple Property Optimization
- Interpreting SAR with Assay and Structural Evidence
- Selecting Robust Chemical Series for Lead Development
32Physicochemical Properties and Drug-Like Behavior10 temas
- Solubility and Dissolution in Relevant Environments
- Lipophilicity and Distribution Coefficients
- Ionization and pKa
- Molecular Size, Polarity, and Hydrogen Bonding
- Permeability and Membrane Partitioning
- Solid-State Form and Physical Stability
- Chemical Stability and Reactive Liabilities
- Property Tradeoffs Across Therapeutic Modalities
- Empirical Guidelines and Their Applicability Limits
- Connecting Molecular Properties to Exposure and Formulation Feasibility
33Selectivity and Polypharmacology10 temas
- On-Target and Off-Target Activity Profiles
- Selectivity Within Protein Families
- Binding Selectivity and Functional Selectivity
- Tissue Context and Effective Selectivity
- Secondary Pharmacology Panels
- Beneficial and Undesirable Multi-Target Effects
- Concentration-Dependent Loss of Selectivity
- Translating Selectivity Margins into Exposure Context
- Distinguishing Mechanistic Toxicity from Promiscuous Activity
- Designing an Evidence-Based Selectivity Strategy
34Enzyme-Targeted Drug Discovery10 temas
- Catalytic Mechanisms and Therapeutic Intervention Points
- Competitive and Noncompetitive Inhibition Concepts
- Allosteric Modulation of Enzyme Activity
- Reversible and Time-Dependent Inhibition
- Substrate Concentration and Apparent Potency
- Cofactors and Assay Context
- Enzyme Turnover and Duration of Effect
- Selectivity Across Related Enzymes
- Cellular Substrate and Product Readouts
- Connecting Enzyme Modulation to Disease-Relevant Outcomes
35Receptor-Targeted Drug Discovery10 temas
- Agonism, Antagonism, and Partial Agonism
- Constitutive Activity and Inverse Agonism
- Orthosteric and Allosteric Binding
- Receptor Reserve and Assay Sensitivity
- Pathway Bias and Functional Readout Dependence
- Receptor Internalization and Desensitization
- Ligand Binding Kinetics and Effect Duration
- Selectivity Across Receptor Subtypes
- Native Tissue Context and Receptor Expression
- Translating Receptor Pharmacology into a Candidate Profile
36Ion Channel and Transporter Discovery10 temas
- Channel Gating and State-Dependent Modulation
- Transporter Function and Substrate Competition
- Electrophysiological and Surrogate Readouts
- Use Dependence and Kinetic Effects
- Membrane Potential and Assay Context
- Selectivity Across Related Channels and Transporters
- Tissue Distribution and Safety Relevance
- Cell-Based Confirmation of Functional Modulation
- Exposure Requirements at the Relevant Membrane Compartment
- Balancing Therapeutic Activity with Excitability-Related Risk
37Protein-Protein Interaction Modulators10 temas
- Interaction Interfaces and Hot Spots
- Stabilization and Disruption of Molecular Complexes
- Shallow Surfaces and Nontraditional Binding Sites
- Small Molecules, Peptides, and Biologic Approaches
- Conformational Dynamics of Interaction Partners
- Assay Design for Complex Formation
- Binding and Functional Consequences
- Intracellular Access and Target Engagement
- Selectivity Among Related Interaction Networks
- Demonstrating Disease-Relevant Modulation of a Protein Complex
38Covalent Drug Discovery10 temas
- Reversible and Irreversible Covalent Engagement
- Recognition-Driven and Nonspecific Reactivity
- Target Residue Accessibility and Context
- Time-Dependent Potency and Engagement Kinetics
- Target Turnover and Duration of Activity
- Proteome-Wide Selectivity Assessment
- Reactive Metabolites and Safety Concerns
- Cellular Confirmation of Covalent Engagement
- Exposure-Engagement Relationships
- Balancing Durable Activity with Chemical and Biological Selectivity
39Targeted Protein Degradation and Proximity-Induced Medicines10 temas
- Event-Driven and Occupancy-Driven Pharmacology
- Heterobifunctional Degraders and Molecular Glues
- Ternary Complex Formation and Cooperativity
- Degradation Potency and Maximum Effect
- Protein Resynthesis and Recovery Kinetics
- Tissue Context and Machinery Availability
- Selectivity Beyond Simple Binary Binding
- Permeability and Molecular Property Challenges
- Resistance and Mechanistic Confirmation
- Emerging Proximity-Induced Functions Beyond Degradation
40Small-Molecule Targeting of RNA and Gene Regulation10 temas
- RNA Structure and Accessible Binding Features
- Transcript-Specific and Context-Dependent Recognition
- Splicing Modulation as a Therapeutic Strategy
- RNA Stability and Translation Modulation
- RNA-Protein Complexes as Intervention Points
- Cellular RNA Abundance and Target Availability
- Selectivity Across the Transcriptome
- Direct Binding and Downstream Expression Effects
- Transcript-Level and Protein-Level Confirmation
- Connecting RNA Modulation to Therapeutic Benefit
41Peptide and Macrocyclic Therapeutics10 temas
- Linear, Cyclic, and Constrained Peptide Architectures
- Binding Surface Recognition and Specificity
- Proteolytic Stability and Half-Life
- Cell Penetration and Tissue Access
- Conformational Control and Cyclization
- Chemical Modification and Conjugation Strategies
- Solubility and Aggregation Liabilities
- Route of Administration and Formulation Constraints
- Functional Optimization and Developability
- Comparing Peptides with Small-Molecule and Protein Alternatives
Etapa 4
Biologics & Advanced Modalities
Anticuerpos, ARN, células, conjugados
17 módulos · 170 temas
42Recombinant Protein Therapeutics10 temas
- Replacement, Supplementation, and Modulation Strategies
- Protein Sequence and Functional Domain Design
- Folding and Structural Integrity
- Post-Translational Modifications and Biological Activity
- Proteolysis, Aggregation, and Stability
- Half-Life Extension Concepts
- Tissue Distribution and Receptor Interactions
- Potency and Mechanism-Relevant Characterization
- Immunogenicity and Endogenous Protein Relationships
- Connecting Molecular Design to a Practical Therapeutic Product
43Therapeutic Antibody Discovery10 temas
- Antigen Selection and Biological Relevance
- Epitope Accessibility and Functional Consequences
- Antibody Discovery Platforms
- Binding Affinity and Kinetic Profiles
- Functional Screening Beyond Antigen Binding
- Agonistic, Antagonistic, and Depleting Mechanisms
- Cross-Species Reactivity and Development Models
- Sequence Diversity and Candidate Families
- Early Liability Screening
- Selecting Antibody Leads Against the Target Product Profile
44Antibody Engineering and Optimization10 temas
- Humanization and Sequence Refinement
- Affinity Maturation and Functional Tradeoffs
- Fc-Mediated Effector Functions
- Fc Receptor Interactions and Recycling
- Half-Life and Exposure Engineering
- Aggregation, Solubility, and Self-Association
- Chemical Modification Hot Spots
- Immunogenicity-Related Sequence Assessment
- Format Selection and Administration Requirements
- Integrated Optimization of Activity, Safety, and Developability
45Bispecific and Multispecific Biologics10 temas
- Dual-Target and Multi-Target Therapeutic Rationale
- Molecular Geometry and Spatial Constraints
- Valency, Affinity, and Avidity
- Simultaneous and Sequential Target Engagement
- Cell Bridging and Conditional Activity
- Chain Pairing and Product Heterogeneity
- Tissue Distribution and Antigen Sink Effects
- Functional Potency and Context Dependence
- Safety Risks from Unintended Cellular Interactions
- Candidate Selection Across Complex Molecular Formats
46Antibody-Drug Conjugates and Targeted Payload Delivery10 temas
- Target Selection and Tissue Expression
- Antibody Internalization and Intracellular Trafficking
- Linker Stability and Release Mechanisms
- Payload Class and Biological Effect
- Drug-to-Antibody Ratio and Product Heterogeneity
- Bystander Activity and Tissue Context
- Systemic Exposure to Intact and Released Components
- Target-Dependent and Target-Independent Toxicity
- Resistance and Biomarker Strategy
- Integrating Antibody, Linker, and Payload Performance
47Therapeutic Enzymes and Enzyme Replacement10 temas
- Enzyme Activity as the Therapeutic Function
- Substrate Accessibility in Disease Compartments
- Intracellular Targeting and Uptake
- Cofactor Dependence and Physiological Conditions
- Circulating Stability and Tissue Retention
- Substrate Reduction and Biochemical Endpoints
- Immune Responses to Therapeutic Enzymes
- Enzyme Activity and Clinically Relevant Exposure
- Functional Comparability Across Product Variants
- Linking Biochemical Correction to Patient Benefit
48Cytokines, Growth Factors, and Immune-Modulating Proteins10 temas
- Receptor Networks and Pleiotropic Effects
- Potency, Selectivity, and Cell-Type Responses
- Short Half-Life and Exposure Constraints
- Local and Systemic Activity
- Engineered Receptor Bias and Conditional Activation
- Fusion Formats and Targeted Delivery Concepts
- Immune Activation and Safety Margins
- Pharmacodynamic Markers of Pathway Modulation
- Combination Opportunities and Interaction Risks
- Balancing Immune Function with Tolerability
49Oligonucleotide Therapeutics10 temas
- Antisense, RNA Interference, and Aptamer Modalities
- Sequence Recognition and Mechanism of Action
- Chemical Modifications and Stability
- Tissue Uptake and Intracellular Trafficking
- Endosomal Escape and Functional Availability
- Transcript Isoforms and Target Site Selection
- Sequence-Dependent and Sequence-Independent Effects
- Protein Binding and Distribution
- Duration of Gene Modulation
- Candidate Evaluation from Target Engagement to Functional Outcome
50mRNA-Based Therapeutic Platforms10 temas
- Encoded Protein and Therapeutic Rationale
- Transcript Design Attributes Relevant to Drug Development
- Translation, Persistence, and Protein Production
- Innate Immune Recognition and Biological Response
- Delivery Formulation and Tissue Distribution
- Transient Expression and Repeat Administration
- Protein Localization and Functional Activity
- Product Integrity and Impurity Considerations
- Exposure and Pharmacodynamic Measurement Challenges
- Linking Expression Profiles to a Therapeutic Window
51Gene Addition and Gene Replacement Therapies10 temas
- Therapeutic Gene Function and Disease Mechanism
- Vector and Nonvector Delivery Choices
- Tissue Tropism and Target Cell Access
- Expression Level, Duration, and Regulation
- Episomal Persistence and Genomic Integration Considerations
- Preexisting Immunity and Treatment Eligibility
- Biodistribution and Off-Tissue Expression
- Durability, Redosing, and Long-Term Follow-Up
- Potency and Functional Correction
- Connecting Product Design to a Clinically Meaningful Outcome
52Therapeutic Genome and Epigenome Editing10 temas
- In Vivo and Ex Vivo Treatment Architectures
- Correction, Disruption, and Regulatory Modification Goals
- Editing Modality and Disease-Specific Suitability
- Delivery to the Clinically Relevant Cell Population
- Mosaic Outcomes and Required Fraction of Corrected Cells
- Unintended Genomic and Cellular Consequences
- Persistence of Editing Components
- Functional Restoration and Long-Term Stability
- Patient Genotype and Treatment Eligibility
- Translational Evidence Beyond Editing Percentage Alone
53Cell-Based Therapeutic Products10 temas
- Autologous and Allogeneic Treatment Strategies
- Immune, Stem, and Differentiated Cell Modalities
- Cell Identity and Intended Biological Function
- Functional Engineering and Phenotype Stability
- Expansion, Persistence, and Tissue Localization
- Host Compatibility and Immune Rejection
- Uncontrolled Growth and Other Product-Specific Risks
- Potency Assays and Clinically Relevant Function
- Administration Logistics and Chain of Identity
- Linking Cellular Attributes to Safety and Clinical Performance
54Vaccine Discovery and Pharmaceutical Biotechnology10 temas
- Antigen Selection and Immune Response Goals
- Protein, Nucleic Acid, and Vector Platform Concepts
- Antigen Presentation and Immune Recognition
- Adjuvants and Formulation Contributions
- Neutralizing and Cellular Immune Readouts
- Correlates of Protection and Their Limitations
- Population, Age, and Prior Exposure Effects
- Immune Durability and Booster Rationale
- Preventive and Therapeutic Vaccine Development Differences
- Translating Immunogenicity into Evidence of Clinical Benefit
55Microbiome-Derived and Live Biotherapeutic Products10 temas
- Defined Organisms, Communities, and Microbial Products
- Mechanistic Hypotheses for Therapeutic Benefit
- Strain Identity and Functional Characterization
- Colonization, Persistence, and Transient Activity
- Host Context and Baseline Microbiome Variation
- Functional Metabolites and Pharmacodynamic Readouts
- Product Consistency and Biological Stability
- Safety Assessment in the Intended Patient Population
- Causal Evidence Beyond Community Composition Changes
- Clinical Evaluation of Product-Specific Benefit
56Radiopharmaceutical and Theranostic Discovery10 temas
- Molecular Targeting and Radionuclide Delivery
- Target Expression and Tissue Accessibility
- Ligand, Chelator, and Radionuclide Compatibility
- Binding, Internalization, and Retention
- Physical Decay and Biological Clearance
- Diagnostic Imaging and Patient Selection
- Tissue Dosimetry and Exposure Heterogeneity
- Therapeutic Index and Off-Target Irradiation
- Product Stability and Time-Sensitive Use Constraints
- Connecting Imaging Evidence to Therapeutic Development Decisions
57Drug Delivery and Tissue Targeting10 temas
- Biological Barriers Between Administration and Target
- Oral, Parenteral, Inhaled, and Local Delivery Concepts
- Tissue Permeability and Cellular Uptake
- Blood-Brain Barrier Access in Discovery Decisions
- Local Retention and Systemic Escape
- Targeted and Passive Distribution Mechanisms
- Release Kinetics and Exposure Duration
- Carrier-Drug Interactions and Product Stability
- Delivery-Related Toxicity and Immune Responses
- Evaluating Functional Delivery Rather Than Material Uptake Alone
58Nanomedicines and Delivery Formulations10 temas
- Lipid, Polymer, and Other Carrier Platforms
- Particle Size, Surface Properties, and Distribution
- Cargo Loading and Encapsulation Attributes
- Protein Corona and Biological Identity
- Intracellular Trafficking and Cargo Release
- Product Heterogeneity and Analytical Characterization
- Carrier and Cargo Pharmacokinetics
- Formulation Stability and Repeat-Dose Considerations
- Scale-Dependent Changes Relevant to Development
- Demonstrating the Contribution of the Delivery System
Etapa 5
Developability, Safety & Candidate Selection
Exposición, seguridad y el no rotundo
18 módulos · 180 temas
59Developability and Candidate Quality10 temas
- Potency and Efficacy Alongside Product Feasibility
- Solubility, Aggregation, and Physical Stability
- Chemical and Enzymatic Degradation
- Expression and Recovery Feasibility for Biologics
- Formulation Compatibility and Administration Constraints
- Product Heterogeneity and Characterization Burden
- Sequence and Structural Liabilities
- Supply, Synthetic Complexity, and Material Availability
- Ranking Candidates with Integrated Developability Data
- Identifying Liabilities Before Expensive Development Commitments
60Immunogenicity Assessment and Mitigation10 temas
- Product, Patient, and Treatment-Related Risk Factors
- Anti-Drug Antibodies and Neutralizing Responses
- Effects on Exposure, Activity, and Safety
- Sequence, Structure, and Aggregation Contributions
- Innate Immune Activation and Adaptive Responses
- Preclinical Models and Human Predictive Limitations
- Immunogenicity Assay Strategy and Drug Interference
- Clinical Sampling and Interpretation
- Comparing Binding Antibodies with Functional Consequences
- Risk Reduction Through Product Design and Evidence Review
61Discovery ADME and Metabolic Stability10 temas
- Absorption, Distribution, Metabolism, and Excretion in Candidate Selection
- Permeability and Transporter Interactions
- Plasma Protein Binding and Unbound Exposure
- Metabolic Stability in Relevant Biological Systems
- Metabolite Identification and Species Differences
- Enzyme Inhibition and Induction Liabilities
- Clearance Mechanisms and Tissue Distribution
- Biological Drug Catabolism and Recycling
- Early Prediction of Exposure-Limiting Properties
- Integrating ADME Findings into Molecular Optimization
62Bioanalytical Methods for Discovery and Development10 temas
- Analyte Definition Across Therapeutic Modalities
- Parent Drug, Metabolites, and Active Components
- Mass Spectrometric and Ligand-Binding Methods
- Total, Free, and Functionally Active Drug Measurements
- Matrix Effects and Sample Stability
- Sensitivity, Selectivity, and Quantification Range
- Reference Materials and Calibration
- Assay Qualification and Validation Concepts
- Interpretation of Below-Quantification Results
- Matching Bioanalytical Strategy to the Development Question
63Pharmacokinetics in Candidate Development10 temas
- Concentration-Time Profiles and Exposure Metrics
- Clearance, Volume of Distribution, and Half-Life
- Bioavailability and Route Dependence
- Dose Proportionality and Nonlinear Kinetics
- Tissue Exposure and Distribution Barriers
- Target-Mediated Drug Disposition
- Accumulation and Repeat Administration
- Species Differences and Human Exposure Prediction
- Population Variability and Covariate Effects
- Using PK Evidence to Compare and Progress Candidates
64Pharmacodynamics and Target Engagement10 temas
- Drug Presence and Biological Action
- Direct and Indirect Target Engagement Measurements
- Target Occupancy and Functional Response
- Proximal Biomarkers and Downstream Effects
- Response Delay and Biological Turnover
- Thresholds, Saturation, and Maximum Effect
- Reversible and Persistent Pharmacodynamic Changes
- Tissue-Specific Engagement and Sampling Limitations
- Separating Pharmacodynamic Activity from Clinical Efficacy
- Defining Evidence of Mechanism for a Development Program
65Exposure-Response and Translational Modeling10 temas
- Linking Exposure, Engagement, Response, and Outcome
- PK-PD Model Structures and Assumptions
- Hysteresis and Delayed Responses
- Disease Progression and Treatment Effects
- Mechanistic and Empirical Model Choices
- Parameter Uncertainty and Identifiability
- Allometric and Physiology-Based Translation Concepts
- Quantitative Systems Pharmacology Applications
- Prospective Model Evaluation
- Using Models to Inform Development Decisions with Explicit Limits
66Biomarker Discovery and Qualification10 temas
- Diagnostic, Prognostic, Predictive, and Pharmacodynamic Biomarkers
- Safety and Response Biomarkers
- Intended Context of Use
- Biological Rationale and Measurement Feasibility
- Analytical Validity and Clinical Validity
- Tissue, Blood, Imaging, and Digital Readouts
- Longitudinal Changes and Within-Patient Variability
- Biomarker Thresholds and Validation Populations
- Surrogate Endpoints and Evidence Requirements
- Translating Discovery Signals into Decision-Ready Biomarkers
67Companion Diagnostics and Patient Selection10 temas
- Treatment Eligibility and Biomarker-Defined Populations
- Diagnostic-Therapeutic Co-Development
- Assay Platform and Specimen Requirements
- Cutoff Selection and Classification Error
- Tumor and Tissue Heterogeneity
- Temporal Changes in Biomarker Status
- Diagnostic Performance and Treatment Effect Interpretation
- Retrospective and Prospective Validation
- Access, Turnaround Time, and Clinical Workflow
- Aligning Diagnostic Evidence with the Therapeutic Claim
68Preclinical Efficacy and Proof of Concept10 temas
- Prespecified Efficacy Questions and Success Criteria
- Model Choice and Mechanistic Relevance
- Clinically Relevant Comparators
- Exposure Confirmation in Efficacy Studies
- Dose-Response and Time-Course Evidence
- Biomarker and Functional Outcome Integration
- Durability and Reversibility of Benefit
- Replication Across Models and Biological Contexts
- Negative Results and Alternative Explanations
- Defining a Credible Preclinical Proof-of-Concept Package
69Safety Pharmacology and Secondary Pharmacology10 temas
- Functional Effects on Vital Physiological Systems
- Cardiovascular, Respiratory, and Nervous System Risk Questions
- Off-Target Activity and Mechanistic Follow-Up
- Exposure Margins and Unbound Drug Considerations
- Acute and Delayed Functional Effects
- In Vitro and In Vivo Evidence Integration
- Modality-Specific Safety Concerns
- Species Relevance and Interpretation Limits
- Follow-Up Studies Driven by Observed Signals
- Integrating Functional Safety Findings into Candidate Selection
70Toxicology Strategy for Drug Development10 temas
- Hazard Identification and Exposure Context
- Single and Repeated Administration Studies
- Target Organs and Reversibility of Findings
- Genotoxicity and Carcinogenicity Questions
- Reproductive and Developmental Risk Assessment
- Local Tolerance and Administration-Related Effects
- Biologic and Advanced Modality Considerations
- Immunotoxicity and Immune-Mediated Findings
- Study Design Based on Product and Intended Clinical Use
- Weight-of-Evidence Interpretation of Toxicological Risk
71Human-Relevant Safety Models and New Approach Methodologies10 temas
- Human Cell Models for Toxicity Assessment
- Organotypic Systems and Tissue Chips
- Mechanistic Toxicity Readouts
- In Silico Safety Predictions
- Exposure Matching Across Experimental Systems
- Benchmarking Against Known Human Outcomes
- Applicability Domains and Model Qualification
- Integrating Multiple Nonclinical Evidence Streams
- Opportunities to Reduce Animal Use
- Regulatory Acceptance as a Context-Specific Evidence Question
72Species Relevance and Translational Uncertainty10 temas
- Target Sequence and Functional Conservation
- Differences in Tissue Expression and Pathway Biology
- Cross-Reactivity of Biologic Candidates
- Species-Specific Metabolites and Exposure
- Immune Responses to Human Therapeutic Proteins
- Disease Model and Safety Model Differences
- Surrogate Molecules and Their Limitations
- Human Data Anchors for Translation
- Remaining Unknowns Before Human Studies
- Documenting Assumptions and Alternative Development Scenarios
73Translational Dose and Regimen Selection10 temas
- Integrating Nonclinical Exposure and Response Evidence
- Safety-Based and Pharmacology-Based Starting Dose Concepts
- Minimum Anticipated Biological Effect Level Concepts
- Exposure Margins and Uncertainty Factors
- Escalation Strategy and Predicted Active Exposure
- Duration of Effect and Dosing Interval
- Loading and Maintenance Regimen Rationale
- Route and Formulation Effects on Regimen Choice
- Updating Predictions with Emerging Human Data
- Documented Justification for Protocol-Level Dosing Decisions
74Development Candidate Nomination10 temas
- Candidate Selection Criteria and Evidence Completeness
- Potency, Selectivity, and Mechanistic Confidence
- Exposure and Efficacy at Feasible Administration Conditions
- Preliminary Safety and Therapeutic Window
- Developability and Material Supply Feasibility
- Biomarker and Patient Selection Readiness
- Primary and Backup Candidate Strategies
- Unresolved Liabilities and Mitigation Plans
- Cross-Functional Review and Go-or-No-Go Decisions
- Transition from Discovery Optimization to Formal Development
75Pharmaceutical Development and CMC Interfaces10 temas
- Drug Substance and Drug Product Definitions
- Critical Quality Attributes Relevant to Clinical Performance
- Formulation Selection and Product Presentation
- Analytical Characterization and Product Specifications
- Impurity Profiles and Safety Assessment Interfaces
- Stability and Shelf-Life Development
- Process Changes and Clinical Material Comparability
- Reference Standards and Potency Methods
- Clinical Supply Readiness and Product Accountability
- Handoff to Detailed Bioprocessing and Manufacturing Development
76Preparing the First Clinical Development Package10 temas
- Integrated Pharmacology and Toxicology Evidence
- Product Quality and Clinical Material Documentation
- Proposed Clinical Protocol and Monitoring Strategy
- Investigator Information and Known Risk Communication
- Gaps Requiring Resolution Before Human Exposure
- Interaction Between Scientific and Regulatory Teams
- IND and Clinical Trial Application Concepts
- Agency Scientific Advice and Development Questions
- Readiness Review Across Product, Evidence, and Operations
- Maintaining Traceability from Preclinical Claims to Supporting Data
Etapa 6
Clinical Development & Regulation
Ensayos, reguladores, evidencia
11 módulos · 110 temas
77Early Clinical Development and First-in-Human Studies10 temas
- Primary Objectives of Initial Human Studies
- Healthy Volunteer and Patient Study Contexts
- Single and Multiple Ascending Dose Designs
- Safety Monitoring and Escalation Review
- Human Pharmacokinetics and Exposure Confirmation
- Pharmacodynamic and Target Engagement Readouts
- Food, Formulation, and Administration Questions
- Sentinel and Staggered Enrollment Concepts
- Stopping Rules and Emerging Risk Assessment
- Updating the Development Hypothesis from Early Human Evidence
78Clinical Proof of Concept and Phase II Development10 temas
- Demonstrating Activity in the Intended Patient Population
- Dose and Regimen Exploration
- Endpoint Selection and Measurement Sensitivity
- Biomarker-Enriched and Unselected Populations
- Comparator and Background Therapy Selection
- Treatment Duration and Follow-Up
- Exposure-Response Evidence in Patients
- Efficacy Signals and Uncertainty
- Understanding Negative or Inconclusive Results
- Criteria for Progression to Confirmatory Development
79Confirmatory Clinical Development10 temas
- Translating Product Claims into Trial Objectives
- Clinically Meaningful Endpoints
- Active and Placebo Comparator Considerations
- Background Standard of Care
- Population Definition and External Validity
- Adequate Follow-Up for Benefit and Risk
- Trial Consistency Across Regions and Sites
- Confirmatory Evidence and Supportive Evidence
- Product Quality Consistency During Clinical Development
- Integrating Results into an Overall Benefit-Risk Assessment
80Clinical Trial Design and Statistical Interpretation10 temas
- Randomization, Blinding, and Allocation Concealment
- Hypotheses, Effect Sizes, and Statistical Power
- Estimands and Intercurrent Events
- Missing Data and Sensitivity Analyses
- Multiplicity and Hierarchical Testing
- Time-to-Event and Repeated-Measure Outcomes
- Interim Analyses and Adaptive Features
- Statistical Significance and Clinical Relevance
- Subgroup Findings and Interaction Evidence
- Prespecification, Transparency, and Reproducible Analysis
81Precision Trials and Special Development Contexts10 temas
- Biomarker-Stratified and Enrichment Designs
- Basket, Umbrella, and Platform Trial Concepts
- Rare Disease and Small Population Constraints
- Natural History Data and External Controls
- Pediatric Development and Age-Appropriate Evidence
- Older Adults and Comorbidity Representation
- Organ Impairment and Exposure Variability
- Durable Interventions and Long-Term Follow-Up
- Individualized Therapies and Product Variability
- Matching Design Innovation to the Evidence Question
82Clinical Operations, Ethics, and Data Quality10 temas
- Informed Consent and Participant Understanding
- Ethics Review and Independent Oversight
- Site Selection and Investigator Readiness
- Recruitment, Retention, and Representative Enrollment
- Protocol Feasibility and Participant Burden
- Investigational Product Handling and Accountability
- Risk-Based Monitoring and Data Verification
- Safety Reporting and Escalation Responsibilities
- Privacy, Data Governance, and Research Integrity
- Trial Registration and Responsible Results Disclosure
83Regulatory Development and Evidence Strategy10 temas
- Product Classification and Development Jurisdictions
- Drug, Biologic, and Combination Product Interfaces
- Regulatory Advice and Milestone Planning
- Nonclinical, Clinical, and Quality Evidence Integration
- Common Technical Document Organization Concepts
- Scientific Justification for Development Deviations
- Expedited Programs and Their Evidence Expectations
- Proposed Labeling and Supported Product Claims
- Agency Questions and Benefit-Risk Uncertainty
- Lifecycle Commitments After Initial Authorization
84Integrated Benefit-Risk and Clinical Value Assessment10 temas
- Magnitude and Durability of Therapeutic Benefit
- Severity, Frequency, and Reversibility of Harm
- Disease Context and Available Alternatives
- Patient Preferences and Treatment Burden
- Subpopulation Differences in Benefit and Risk
- Uncertainty from Trial Design and Evidence Gaps
- Absolute and Relative Effect Interpretation
- Generalizability to Clinical Practice
- Risk Mitigation and Monitoring Requirements
- Transparent Communication of the Overall Evidence
85Pharmacovigilance and Post-Authorization Evidence10 temas
- Known Risks, Potential Risks, and Missing Information
- Adverse Event Reports and Signal Detection
- Exposure Denominators and Reporting Bias
- Causality Assessment and Confounding
- Registries and Long-Term Follow-Up
- Real-World Data and Fit-for-Purpose Study Design
- Rare and Delayed Adverse Effects
- Product Quality Signals and Clinical Safety Interfaces
- Risk Management Plans and Label Updates
- Feeding Post-Authorization Findings Back into Research
86Biosimilars, Comparability, and Product Lifecycle Development10 temas
- Biosimilarity and Reference Product Selection
- Analytical Similarity and Functional Characterization
- Residual Uncertainty and Evidence Integration
- Clinical Pharmacology and Comparative Evidence
- Immunogenicity Considerations in Product Comparison
- Manufacturing Changes and Comparability
- Formulation Changes and New Presentations
- Indication Extrapolation as a Scientific Question
- Product-Specific and Jurisdiction-Specific Requirements
- Maintaining Clinical Confidence Throughout the Product Lifecycle
87Resistance, Combination Therapies, and Treatment Evolution10 temas
- Intrinsic and Acquired Resistance Mechanisms
- Target Alteration and Pathway Compensation
- Cellular State Changes and Tissue Microenvironment
- Rational Combination Hypotheses
- Additivity, Synergy, and Antagonism
- Combination Exposure and Safety Interactions
- Scheduling and Sequence of Administration
- Biomarkers of Response and Resistance
- Demonstrating Each Component's Contribution
- Using Treatment Failure to Refine Discovery Programs
Etapa 7
Portfolio, Partnerships & Capstone
Patentes, socios, tu propio programa
3 módulos · 30 temas
88Intellectual Property and Discovery Portfolio Strategy10 temas
- Composition, Use, and Platform Intellectual Property
- Patentability and Freedom-to-Operate Questions
- Data, Materials, and Reagent Ownership
- Licensing and Collaboration Terms as Development Constraints
- Competitive Target and Modality Landscapes
- Scientific Differentiation and Product Differentiation
- Portfolio Balance Across Stages and Risk Types
- Kill Criteria and Opportunity Cost
- Backup Programs and Shared Platform Dependencies
- Evaluating Assets with Transparent Scientific Assumptions
89Translational Project Management and Partnerships10 temas
- Integrated Development Plans and Critical Paths
- Milestone-Based Budgets and Resource Allocation
- Academic-to-Industry Technology Transfer
- CRO, CDMO, Diagnostic, and Clinical Partner Interfaces
- Work Package Specifications and Acceptance Criteria
- Data Quality, Reproducibility, and Vendor Oversight
- Cross-Functional Decision Meetings
- Funding Requirements Across Development Stages
- Scientific Due Diligence and Evidence Rooms
- Preserving Knowledge and Accountability Across Collaborations
90Integrated Drug Discovery and Development Projects10 temas
- Target Validation Plan Anchored in Human Disease Evidence
- Assay Cascade for a Defined Therapeutic Hypothesis
- Hit-to-Lead Strategy with Artifact and Selectivity Controls
- Candidate Comparison Using Potency, Exposure, Safety, and Developability
- Therapeutic Antibody Program from Epitope to Product Profile
- RNA-Based Therapy Assessment with Delivery and Functional Readouts
- Translational Biomarker Plan Connecting Models to Patients
- Preclinical-to-Clinical Readiness Review for a New Candidate
- Clinical Proof-of-Concept Design with Prespecified Decision Criteria
- Integrated Review of Mechanism, Product Quality, Benefit, Risk, and Feasibility
Quince minutos.Cada día.
- 1
Una lección cabe en la pausa de la comida
Una idea cada vez, en diapositivas breves. Una lección entera dura unos quince minutos.
- 2
Práctica con corrección al instante
Las preguntas van dentro de la lección. Responde y ve al instante si lo has entendido.
- 3
Una racha que te hace volver
Una lección al día mantiene viva la racha. Sesiones cortas y constantes te llevan hasta el final.
- 1
Una lección cabe en la pausa de la comida
Una idea cada vez, en diapositivas breves. Una lección entera dura unos quince minutos.
- 2
Práctica con corrección al instante
Las preguntas van dentro de la lección. Responde y ve al instante si lo has entendido.
- 3
Una racha que te hace volver
Una lección al día mantiene viva la racha. Sesiones cortas y constantes te llevan hasta el final.
Para quienes están tras el pipeline.
Biólogos en un equipo de descubrimiento
Químicos que quieren todo el pipeline
Donde más vas a crecer
Lee relaciones estructura-actividad
Etapa 3 · Molecular Design & Medicinal ChemistryClínicos que pasan a la industria
Donde más vas a crecer
Lee con honestidad un ensayo fase II
Etapa 6 · Clinical Development & Regulation
A dónde lleva este curso.
El trabajo en torno al que está construido este curso, y cómo se entra en él.
Discovery Scientist
Hace los experimentos que llevan un programa desde una diana hasta una molécula candidata.
Todas las carreras del futuroEn el trabajo
- Montar y ejecutar los ensayos en los que se apoya un proyecto
- Separar los aciertos reales de los artefactos del ensayo
- Presentar los datos que descartan o hacen avanzar una serie
Cómo se entra
Un título en biología, química o farmacología; muchos puestos de este nivel piden un doctorado o varios años de banco de laboratorio.
Sé de los primeros.
Acceso anticipado para particulares, pilotos para equipos. Cuéntanos quién va a aprender.
enterprise@astratrainer.com